Cellular Systems Core

项目摘要/摘要-资源核心2：蜂窝系统核心 联合生物学联盟(JBC)的研究人员分享了一系列阻碍利用现状的挑战 最先进的关节炎及相关疾病研究技术。在第一个周期取得成功的基础上 JBC，蜂窝系统核心(CSC)将利用当地资源和规模经济来培育 一套集成的研究工具，为JBC成员提供服务。CSC将提供两大类服务。 首先，CSC将提供通过下一代测序实现的技术。其中包括单细胞 RNAseq、ATAC-seq、T细胞和B细胞受体测序、基因组DNA测序、空间转录 基于CRISPR的基因组扰动筛选，以及通过PhIP-Seq和T-Scan检测自身抗原。 其次，CSC将提供以蛋白质检测为中心的工具。其中包括按时间顺序优化的细胞仪 飞行(CyTOF)、组织质量细胞仪和基于Luminex的筛查，实现经济、可定制的检测 细胞因子、抗体和其他蛋白质。 结果数据将通过新的联合生物学联盟生物信息学核心进行分析，提供 为JBC成员提供高端大数据分析和结构化教育和指导，目标是 发展一个熟悉先进计算方法的调查人员社区。 该计划整合了Brigham和妇女医院单细胞基因组学提供的服务 核心和数据科学中心，哈佛医学区细胞飞行核心，波士顿儿童医院 免疫学部，布罗德研究所的基因组微扰平台，以及其他附属核心和 实验室。CSC服务将逐步优化--现在包括细胞和完整的组织-- 进一步通过与加速药物的技术和计算领导者的密切联系 风湿性关节炎和狼疮的伙伴关系(AMP)联盟，确保JBC成员获得最新的 方法论的进步。服务交付将由一个由哈佛大学CyTOF主任组成的科学团队领导 詹姆斯·莱德尔博士得到副主任凯文·韦博士和生物信息学家玛丽亚·古铁雷斯博士的支持- 安塞洛斯。该团队将确保以蜂窝系统核心为代表的物流投资 继续加快JBC内的创新转化性关节炎研究。

PROJECT SUMMARY/ABSTRACT – Resource Core 2: Cellular Systems Core Investigators in the Joint Biology Consortium (JBC) share a set of challenges that impede utilization of state-of- the-art technologies for research in arthritis and related diseases. Building on success in the first cycle of the JBC, the Cellular Systems Core (CSC) will leverage local resources and economies of scale to cultivate an integrated set of research tools to serve JBC members. The CSC will provide two broad categories of service. First, the CSC will deliver technologies realized through next-generation sequencing. These include single-cell RNAseq, ATAC-seq, T- and B-cell receptor sequencing, genomic DNA sequencing, spatial transcriptomics, CRISPR-based genomic perturbation screens, and autoantigen detection through PhIP-seq and T-scan. Second, the CSC will deliver tools centered on protein detection. These include optimized cytometry by time of flight (CyTOF), tissue mass cytometry, and Luminex-based screens for economical, customizable detection of cyctokines, antibodies, and other proteins. Resulting data will be analyzed through the new Joint Biology Consortium Bioinformatics Core, providing both high-end big-data analysis and structured education and coaching for JBC members, with the goal of developing a community of investigators conversant with advanced computational methods. This program integrates services available through the Brigham and Women’s Hospital Single-Cell Genomics Core and Center for Data Sciences, the Harvard Medical Area CyTOF Core, the Boston Children’s Hospital Division of Immunology, the Broad Institute’s Genomic Perturbation Platform, and other affiliated cores and labs. Progressive optimization of CSC services – now encompassing both cells and intact tissues – will result further through close affiliation with technical and computational leaders of the Accelerating Medicines Partnership (AMP) consortium in rheumatoid arthritis and lupus, ensuring JBC members access to the latest methodologic advances. Service delivery will be led by a scientific team consisting of Harvard CyTOF director Dr. James Lederer supported by associate directors Dr. Kevin Wei and bioinformatician Dr. Maria Gutierrez- Arcelus. This team will ensure that the logistical investment represented by the Cellular Systems Core continues to accelerate innovative translational arthritis research within the JBC.